Sign in Subscribe
Pharmaceutical industry

Denosumab Increases Bone Strength by Reducing Bone Remodeling and Preserving Bone Mass

Strategic Insights

— 1 min read

Denosumab, a fully human monoclonal antibody, has been shown to reduce bone turnover markers and increase bone mass, density, and strength in ovariectomized cynomolgus monkeys. This research indicates that denosumab may be effective in preventing bone loss and reducing the risk of fractures in osteoporotic women. The study found that denosumab decreased bone resorption, increased bone mineral density (BMD), and reduced the risk of fractures in osteoporotic women.

Key Takeaways:

  • Denosumab, a fully human monoclonal antibody, inhibits RANKL, a protein essential for osteoclast formation, function, and survival.
  • Osteoclast inhibition with denosumab decreased bone resorption, increased bone mineral density (BMD), and reduced fracture risk in osteoporotic women.
  • The study found that denosumab reduced bone turnover markers CTx and BSAP, consistent with reduced bone remodeling.
  • Increased remodeling in the control group led to absolute declines in areal BMD of 4.3-7.4% at the lumbar spine, total hip, femur neck, and distal radius.
  • Denosumab increased bone mass and preserved bone quality, indicating that it may be effective in preventing bone loss and reducing the risk of fractures in osteoporotic women.

Statistics:

  • 14-20 cynomolgus monkeys were treated with subcutaneous vehicle (OVX-Veh) or denosumab (25 or 50mg/kg) per month.
  • Sham-operated controls were treated with vehicle (n=17).
  • The study found that denosumab reduced bone resorption by 23.4% at the lumbar spine.
  • Areal BMD decreased by 4.3-7.4% in the control group at various skeletal sites.
  • Denosumab increased bone mass by 14.5% at the lumbar spine.

Sources:

  • Ominsky, M. S., Vaisberg, E. J., Marion, N. M., Li, X., Asuncion, F. J., Chen, W., ... & Kostenik, P. J. (2011). Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys. Bone, 49(2), 162-173.
  • Amgen Inc. (2011). Metabolic Disorders Research.

Read more